Industry makes strides in melanoma.
Garber
Ken
K
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015703:Antigens, CD / Q000187:drug effects; D060908:CTLA-4 Antigen; D017321:Clinical Trials, Phase I as Topic; D017326:Clinical Trials, Phase III as Topic; D004345:Drug Industry / Q000639:trends*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D000074324:Ipilimumab; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D047428:Protein Kinase Inhibitors; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors; D012878:Skin Neoplasms / Q000276:immunology / Q000628:therapy*; D013449:Sulfonamides / Q000627:therapeutic use*; D016896:Treatment Outcome; D000077484:Vemurafenib
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D007211:Indoles; D000074324:Ipilimumab; D047428:Protein Kinase Inhibitors; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf